Table 3.

Candidate predictors and clinical outcomes.

		Tumor response, RECIST		Early tumor shrinkage		Skin rash until 8 weeks		Progression-free survival		Overall survival
	N	CR, PR	SD, PD	Yes	No	Gr0-1	Gr2-3	Median (95%CI), months	HR (95%CI)	Median (95%CI), months	HR (95%CI)
AREG
≤1.59	13	7 (54%)	6 (46%)	10 (77%)	3 (23%)	7 (64%)	4 (36%)	6.6 (3.0, 13.8)	1	26.5 (5.7, 33.9)	1
>1.59	54	43 (83%)	9 (17%)	43 (83%)	9 (17%)	34 (71%)	14 (29%)	11.6 (9.4, 14.9)	0.52 (0.28, 0.98)	42.8 (27.1, 42.9+)	0.50 (0.22, 1.13)
P*			0.30		0.69		0.72		0.037		0.084
EREG
≤3.21	41	30 (75%)	10 (25%)	30 (75%)	10 (25%)	29 (78%)	8 (22%)	11.0 (8.8, 14.7)	1	33.9 (21.5, 41.1+)	1
>3.21	23	19 (86%)	3 (14%)	20 (91%)	2 (9%)	11 (58%)	8 (42%)	11.2 (7.0, 15.2)	0.90 (0.50, 1.60)	42.8 (27.1, 42.9+)	0.66 (0.29, 1.51)
P*			0.98		0.18		0.13		0.70		0.29
EGFRGCN
Low	47	33 (75%)	11 (25%)	36 (82%)	8 (18%)	25 (61%)	16 (39%)	9.1 (5.8, 11.7)	1	27.1 (18.3, 42.8)	1
High	30	23 (79%)	6 (21%)	22 (76%)	7 (24%)	20 (77%)	6 (23%)	11.6 (9.2, 15.2)	0.63 (0.38, 1.07)	41.4+ (23.2, 41.4+)	0.52 (0.25, 1.08)
P*			0.78		0.57		0.20		0.073		0.068
EGFRCA-SSR1
LL	36	24 (73%)	9 (27%)	25 (76%)	8 (24%)	20 (67%)	10 (33%)	11.1 (8.9, 13.6)	1	27.1 (19.0, 42.8)	1
SL	29	23 (79%)	6 (21%)	23 (79%)	6 (21%)	21 (81%)	5 (19%)	9.1 (6.6, 14.5)	0.88 (0.51, 1.52)	42.9+ (20.0, 42.9+)	0.62 (0.30, 1.30)
SS	12	9 (82%)	2 (18%)	10 (91%)	1 (9%)	4 (36%)	7 (64%)	15.2 (3.0, 17.4)	0.75 (0.34, 1.63)	39.8+ (12.6, 39.8+)	0.56 (0.19, 1.64)
P*			0.75		0.63		0.040		0.74		0.32

^*P values were based on Fisher's exact for tumor response, early tumor shrinkage, and skin rash until 8 weeks except for AREG and EREG based on maximal chi-square method for tumor response, log-rank test for PFS and OS in the univariate analysis.

Bold characters; significant, +; Estimates were not reached.